Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Baert

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Inflammatory Bowel Diseases|November 10, 2025
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's DiseaseSuzanne I Anjie, Geert R D'Haens, Filip Baert, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2022
Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutionsStefan Schreiber, Peter M Irving, Ala I Sharara, et al.
Inflammatory Bowel Diseases|February 21, 2012
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseGeert D'Haens, Marc Ferrante, Severine Vermeire, et al.
Inflammatory Bowel Diseases|June 20, 2018
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART CohortPeter Bossuyt, Filip Baert, Francois D'Heygere, et al.
Journal of Clinical Gastroenterology|February 20, 2026
Development of an Evidence-based Quality Indicator Set for Patients With Inflammatory Bowel Disease in BelgiumLiselotte Fierens, Claire Liefferinckx, João Sabino, et al.
Journal of Crohn'S & Colitis|June 29, 2022
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort StudyAurelien Amiot, Jean-Francois Rahier, Filip Baert, et al.
Gastroenterology|April 13, 2005
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trialPaul Rutgeerts, Gert Van Assche, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|April 19, 2018
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort StudySaartje Van de Vondel, Filip Baert, Christine Reenaers, et al.
Gastroenterology|January 10, 2002
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-upFilip Baert, Alain Schmit, Geert D'Haens, et al.
BMC Cancer|May 13, 2010
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomasNancy Van Damme, Philippe Deron, Nadine Van Roy, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Inflammatory Bowel Diseases|November 10, 2025
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's DiseaseSuzanne I Anjie, Geert R D'Haens, Filip Baert, et al.
Alimentary Pharmacology & Therapeutics|February 8, 2022
Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutionsStefan Schreiber, Peter M Irving, Ala I Sharara, et al.
Inflammatory Bowel Diseases|February 21, 2012
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel diseaseGeert D'Haens, Marc Ferrante, Severine Vermeire, et al.
Inflammatory Bowel Diseases|June 20, 2018
Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART CohortPeter Bossuyt, Filip Baert, Francois D'Heygere, et al.
Journal of Clinical Gastroenterology|February 20, 2026
Development of an Evidence-based Quality Indicator Set for Patients With Inflammatory Bowel Disease in BelgiumLiselotte Fierens, Claire Liefferinckx, João Sabino, et al.
Journal of Crohn'S & Colitis|June 29, 2022
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort StudyAurelien Amiot, Jean-Francois Rahier, Filip Baert, et al.
Gastroenterology|April 13, 2005
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trialPaul Rutgeerts, Gert Van Assche, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|April 19, 2018
Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort StudySaartje Van de Vondel, Filip Baert, Christine Reenaers, et al.
Gastroenterology|January 10, 2002
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-upFilip Baert, Alain Schmit, Geert D'Haens, et al.
BMC Cancer|May 13, 2010
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomasNancy Van Damme, Philippe Deron, Nadine Van Roy, et al.
Pageof 10